TAK-360

Phase 2Small molecule

Takeda

TAK-360 is one of 39 small molecule programs targeting Idiopathic Hypersomnia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic HypersomniaActive, not recruiting

NarcolepsyActive, not recruiting

Narcolepsy Type 1Recruiting

Idiopathic HypersomniaPhase 2

Active, not recruiting

NarcolepsyPhase 2

Active, not recruiting

Narcolepsy Type 1Phase 2

Recruiting

Competition

Competitive Landscape

40 competitors in Narcolepsy

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

—2

Romazicon

CConrado Roberto Hoffmann Filho

Approved

—3

Vivarin

HHikma Pharmaceuticals LLC

Provigil

3 5

Nuvigil

NNuvo Research GmbH

Phase 3

2 6

JZP-258

Jazz Pharmaceuticals

Approved

2 7

Xyrem

Jazz Pharmaceuticals

Phase 3

4 8

JZP258

Jazz Pharmaceuticals

Approved

1 9

Vigil™

GGradalis, Inc.

Phase 3

1 10

TAK-861

Takeda

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Idiopathic Hypersomnia

NCT06812078

Phase 2Recruiting

Narcolepsy

NCT06952699

Q4 2027

Phase 2Recruiting

Narcolepsy Type 1

NCT07633301

Q2 2031

PreclinicalRecruiting

Idiopathic Hypersomnia

NCT07646678

Clinical

Trials by Indication[1]

Idiopathic Hypersomnia2 trials

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

Recruiting· Takeda logo

Takeda·Phase 2·NCT06812078·96 enrolled

A Long-term Extension Trial to Evaluate the Safety and Tolerability of TAK-360 in Participants With Selected Central Hypersomnia Conditions

Recruiting· Takeda logo

Takeda·Preclinical·NCT07646678·500 enrolled

Narcolepsy1 trial

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

Recruiting· Takeda logo

Takeda·Phase 2·NCT06952699·88 enrolled

Narcolepsy Type 11 trial

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)

Recruiting· Takeda logo

Takeda·Phase 2·NCT07633301·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for TAK-360. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-360 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-360. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Takeda

TAK-360

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2027

Q2 2031

Trials by Indication[1]

Idiopathic Hypersomnia2 trials

Narcolepsy1 trial

Narcolepsy Type 11 trial

References

Drug Info

Quick Facts

Related News